TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ST of TN-Salud Con La Familia: Prevent Onset of Ped Obesity
Brief Summary: Preventing the onset of pediatric obesity and diabetes in Latino families

The investigators will conduct a randomized controlled trial of a family-based community centered intervention. One-hundred Latino families with children ages 3-5 will be randomly allocated to either the intervention group (a 3-month skills building program to improve nutrition and aerobic activity for child-parent dyads) or a control group (literacy promotion). Through an active partnership with Nashville Metro Parks and Recreation and the Division of General Pediatrics at the Vanderbilt Children's Hospital, the investigators will: 1) Implement an intervention for Latino families with young children that includes parent training, behavior modification training, nutrition education, and physical activity promotion; 2) Evaluate how this intervention affects growth trajectories in children; 3) Evaluate how this intervention affects parenting practices for Latino families to improve nutrition and physical activity; and 4) Evaluate the ability to link families into a pediatric medical home if they have none identified. By developing innovative family-focused interventions, finding solutions to health conditions such as obesity and diabetes could be realized-con la familia.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Intervention group
B: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Lifestyle counseling; Assigned to Arm(s): Lifestyle counseling
C: Arm Label: Entree energy density 100%; Type: EXPERIMENTAL; Interventions: Other: Energy density feeding study | Arm Label: Entree energy density 85%; Type: EXPERIMENTAL; Interventions: Other: Energy density feeding study | Arm Label: Entree energy density 75%; Type: EXPERIMENTAL; Interventions: Other: Energy density feeding study | Intervention Type: OTHER; Name: Energy density feeding study; Assigned to Arm(s): Entree energy density 100%, Entree energy density 75%, Entree energy density 85%
D: Arm Label: National Vaccine Program Plus Radio; Type: EXPERIMENTAL; Interventions: Behavioral: Appropriate complementary feeding messages | Arm Label: Comparison (no intervention); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Appropriate complementary feeding messages; Assigned to Arm(s): National Vaccine Program Plus Radio

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission (ADMIRE)
Brief Summary: The purpose of this pilot study is to investigate the possibility of discontinuing adalimumab therapy in patients with rheumatoid arthritis who are in stable remission after treatment with adalimumab in combination with methotrexate.


Options:
A: Arm Label: CZP 200 mg Q2W + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX) | Arm Label: CZP 200 mg Q4W + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX) | Arm Label: Placebo + Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo + Methotrexate (MTX) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol + Methotrexate (MTX); Assigned to Arm(s): CZP 200 mg Q2W + Methotrexate, CZP 200 mg Q4W + Methotrexate | Intervention Type: BIOLOGICAL; Name: Placebo + Methotrexate (MTX); Assigned to Arm(s): Placebo + Methotrexate
B: Arm Label: Adalimumab + MTX; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: methotrexate | Arm Label: Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: methotrexate | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab + MTX | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Adalimumab + MTX, Methotrexate
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 3
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Arm Label: Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Group B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of High Dose Atorvastatin Loading in ST Elevation Myocardial Infarction
Brief Summary: Although statin prior to PCI has favorable effects in stable angina and ACS except ST elevation MI (STEMI), there have been few studies for STEMI. Celik T et al. reported in patients with STEMI that prior statin use may improve coronary blood flow after PCI in patients with AMI, possibly by its beneficial effects on microvascular function. But this study was retrospective, non-randomized study and evaluated the effects for chronic statin therapy not acute high dose effect. Therefore, the investigators investigated whether acute high-dose statin prior to primary PCI in ST segment elevation myocardial infarction can have beneficial effect or not for periprocedural period and 30 days-cardiac events.


Options:
A: Arm Label: High dose Atorvastatin 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Control, High dose Atorvastatin 80 mg
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: treatment; Type: EXPERIMENTAL; Interventions: Drug: Simvastatin | Arm Label: untreated; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): treatment
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: atorvastatin | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomised, Placebo and Mesalazine Controlled Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Active Colitis
Brief Summary: The purpose of the study is to obtain a first clinical assessment of the safety of dersalazine sodium in ulcerative colitis patients with mild to moderate disease.


Options:
A: Arm Label: Dersalazine; Type: EXPERIMENTAL; Interventions: Drug: Dersalazine sodium | Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dersalazine sodium; Assigned to Arm(s): Dersalazine | Intervention Type: DRUG; Name: Mesalazine; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: mesalazine; Assigned to Arm(s): N/A
C: Arm Label: Mesalamin; Type: EXPERIMENTAL; Interventions: Drug: Mesalamin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mesalamin | Intervention Type: DRUG; Name: Mesalamin; Assigned to Arm(s): Mesalamin, Placebo
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: mesalazine | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: mesalazine; Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomised, Placebo and Mesalazine Controlled Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Active Colitis
Brief Summary: The purpose of the study is to obtain a first clinical assessment of the safety of dersalazine sodium in ulcerative colitis patients with mild to moderate disease.


Options:
A: Arm Label: Dersalazine; Type: EXPERIMENTAL; Interventions: Drug: Dersalazine sodium | Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dersalazine sodium; Assigned to Arm(s): Dersalazine | Intervention Type: DRUG; Name: Mesalazine; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1: budesonide-MMX® 6 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: budesonide-MMX® 6 mg | Arm Label: 2: budesonide-MMX® 9 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: budesonide-MMX® 9 mg | Arm Label: 3: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Placebo | Arm Label: 4: Asacol® 400 mg; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Asacol® 400 mg | Intervention Type: PROCEDURE; Name: Blood sampling, endoscopy; Assigned to Arm(s): 1: budesonide-MMX® 6 mg, 2: budesonide-MMX® 9 mg, 3: Placebo, 4: Asacol® 400 mg | Intervention Type: DRUG; Name: budesonide-MMX® 6 mg; Assigned to Arm(s): 1: budesonide-MMX® 6 mg | Intervention Type: DRUG; Name: budesonide-MMX® 9 mg; Assigned to Arm(s): 2: budesonide-MMX® 9 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3: Placebo | Intervention Type: DRUG; Name: Asacol® 400 mg; Assigned to Arm(s): 4: Asacol® 400 mg
C: Arm Label: Mesalamin; Type: EXPERIMENTAL; Interventions: Drug: Mesalamin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Mesalamin | Intervention Type: DRUG; Name: Mesalamin; Assigned to Arm(s): Mesalamin, Placebo
D: Arm Label: Mesalazine once/day; Type: EXPERIMENTAL; Interventions: Drug: Mesalazine slow-release granules, Drug: Mesalazine liquid enema | Arm Label: Mesalazine twice/day; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine slow-release granules, Drug: Mesalazine liquid enema | Intervention Type: DRUG; Name: Mesalazine slow-release granules; Assigned to Arm(s): Mesalazine once/day, Mesalazine twice/day | Intervention Type: DRUG; Name: Mesalazine liquid enema; Assigned to Arm(s): Mesalazine once/day, Mesalazine twice/day

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Investigation of Clinical Tolerance, Cardio-respiratory Response and Muscle Fatigue During Electrostimulation
Brief Summary: The study was designed to test the following hypothesis

Patients with high cardio-respiratory response to electrostimulation (ES), high perception of pain during ES and high ES-induced muscle fatigue, have low tolerance to ES (more difficulties to increase intensity during training).


Options:
A: Intervention Type: DEVICE; Name: Neuromuscular Electrical stimulator (Cefar rehab 4 pro); Assigned to Arm(s): N/A
B: Arm Label: ES; Type: ACTIVE_COMPARATOR; Interventions: Device: Electrostimulation | Arm Label: Sham ES; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham stimulation | Intervention Type: DEVICE; Name: Electrostimulation; Assigned to Arm(s): ES | Intervention Type: DEVICE; Name: Sham stimulation; Assigned to Arm(s): Sham ES
C: Arm Label: No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Electrical Stimulation; Type: EXPERIMENTAL; Interventions: Device: Electrical Stimulation | Intervention Type: DEVICE; Name: Electrical Stimulation; Assigned to Arm(s): Electrical Stimulation
D: Arm Label: Neuromuscular Electrical Stimulation (NMES); Type: EXPERIMENTAL; Interventions: Device: Neuromuscular Electrical Stimulation (NMES) | Arm Label: Standard Rehabilitation Protocol; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Rehabilitation Protocol | Intervention Type: DEVICE; Name: Neuromuscular Electrical Stimulation (NMES); Assigned to Arm(s): Neuromuscular Electrical Stimulation (NMES) | Intervention Type: OTHER; Name: Standard Rehabilitation Protocol; Assigned to Arm(s): Standard Rehabilitation Protocol

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Investigation of Clinical Tolerance, Cardio-respiratory Response and Muscle Fatigue During Electrostimulation
Brief Summary: The study was designed to test the following hypothesis

Patients with high cardio-respiratory response to electrostimulation (ES), high perception of pain during ES and high ES-induced muscle fatigue, have low tolerance to ES (more difficulties to increase intensity during training).


Options:
A: Arm Label: Functional electrical stimulation; Type: EXPERIMENTAL; Interventions: Procedure: Functional electrical stimulation | Arm Label: Medium-frequency alternating current; Type: EXPERIMENTAL; Interventions: Procedure: Medium-frequency alternating current | Arm Label: Burst-modulated alternating current; Type: EXPERIMENTAL; Interventions: Procedure: Burst-modulated alternating current | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Placebo | Intervention Type: PROCEDURE; Name: Medium-frequency alternating current; Assigned to Arm(s): Medium-frequency alternating current | Intervention Type: PROCEDURE; Name: Burst-modulated alternating current; Assigned to Arm(s): Burst-modulated alternating current | Intervention Type: PROCEDURE; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: PROCEDURE; Name: Functional electrical stimulation; Assigned to Arm(s): Functional electrical stimulation
B: Intervention Type: DEVICE; Name: Neuromuscular Electrical stimulator (Cefar rehab 4 pro); Assigned to Arm(s): N/A
C: Arm Label: NMES group; Type: EXPERIMENTAL; Interventions: Other: Neuromuscular electrical stimulation, Other: Endurance training, Other: Quadriceps strength training | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Other: Endurance training, Other: Quadriceps strength training | Intervention Type: OTHER; Name: Neuromuscular electrical stimulation; Assigned to Arm(s): NMES group | Intervention Type: OTHER; Name: Endurance training; Assigned to Arm(s): Control group, NMES group | Intervention Type: OTHER; Name: Quadriceps strength training; Assigned to Arm(s): Control group, NMES group
D: Arm Label: One single arm group; Type: EXPERIMENTAL; Interventions: Device: FES-cycling, Device: Classic cycloergometer | Intervention Type: DEVICE; Name: FES-cycling; Assigned to Arm(s): One single arm group | Intervention Type: DEVICE; Name: Classic cycloergometer; Assigned to Arm(s): One single arm group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind Randomized Clinical Trial of the Efficacy of IM Midazolam Versus IV Lorazepam in the Pre-hospital Treatment of Status Epilepticus by Paramedics
Brief Summary: The goal of this non-inferiority trial is to determine which type of routine care is the best for paramedics to stop someone from seizing.


Options:
A: Arm Label: Intramuscular (IM) anticonvulsant; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intramuscular route of active treatment | Arm Label: Intravenous (IV) anticonvulsant; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous route of active treatment | Intervention Type: DRUG; Name: Intramuscular route of active treatment; Assigned to Arm(s): Intramuscular (IM) anticonvulsant | Intervention Type: DRUG; Name: Intravenous route of active treatment; Assigned to Arm(s): Intravenous (IV) anticonvulsant
B: Arm Label: 1 drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diclofenac, Paracetamol, Ibuprofen | Arm Label: 2 drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: Diclofenac, Paracetamol, Ibuprofen | Arm Label: 3 drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diclofenac, Paracetamol, Ibuprofen | Arm Label: 4 drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diclofenac, Paracetamol, Ibuprofen | Arm Label: 5 drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: Diclofenac, Paracetamol, Ibuprofen | Intervention Type: DRUG; Name: Diclofenac, Paracetamol, Ibuprofen; Assigned to Arm(s): 1 drug, 2 drug, 3 drug, 4 drug, 5 drug
C: Intervention Type: DRUG; Name: intranasal lorazepam; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: intramuscular paraldehyde; Assigned to Arm(s): N/A
D: Arm Label: Intranasal Midazolam 0.2mg/kg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Arm Label: Rectal Diazepam 0.3-0.5 mg/kg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diazepam | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Intranasal Midazolam 0.2mg/kg | Intervention Type: DRUG; Name: Diazepam; Assigned to Arm(s): Rectal Diazepam 0.3-0.5 mg/kg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Randomised Study of Methotrexate Efficacy Versus Cyclosporine in Moderate to Severe Atopic Dermatitis Patients
Brief Summary: The systemic treatments for moderate to severe atopic dermatitis (AD) are limited to phototherapy and cyclosporine with the risks respectively of either carcinoma, or hypertension or nephropathy.

Methotrexate was effective in 75% of moderate to severe AD patients with good tolerance in an open retrospective study.

We want to confirm our observations: a non inferiority multicenter clinical trial, methotrexate versus cyclosporine, will be conducted in 100 patients for 24 weeks.


Options:
A: Arm Label: Placebo qw; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Other: Background treatment | Arm Label: Dupilumab 200 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Other: Background treatment | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 200 mg qw | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo qw | Intervention Type: OTHER; Name: Background treatment; Assigned to Arm(s): Dupilumab 200 mg qw, Placebo qw
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclosporin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Ciclosporin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 2
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Dupilumab) | Arm Label: Dupilumab 300 mg every 2 weeks (q2w); Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo (for Dupilumab) | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg every 2 weeks (q2w), Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo (for Dupilumab); Assigned to Arm(s): Dupilumab 300 mg every 2 weeks (q2w), Placebo
D: Arm Label: Placebo qw; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 300 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 100 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 100 mg q4w, Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Dupilumab 100 mg q4w, Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo qw

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intervention Development and Pilot for Foster Care Youth
Brief Summary: The purpose of this study is to develop, standardize and provide a preliminary test of a novel intervention for preadolescent maltreated youth in out-of-home care. It is hypothesized that the preventive intervention, which is known as Fostering Healthy Futures (FHF) and which consists of therapeutic skills groups and mentoring, will improve mental health, social, academic and behavioral functioning and reduce youths' initiation of, and participation in, problem behaviors.


Options:
A: Arm Label: Assessment only; Type: ACTIVE_COMPARATOR; Interventions: Other: Assessment | Arm Label: Fostering Healthy Futures (FHF) Assessment + FHF; Type: EXPERIMENTAL; Interventions: Other: Assessment, Behavioral: Fostering Healthy Futures (FHF) | Intervention Type: OTHER; Name: Assessment; Assigned to Arm(s): Assessment only, Fostering Healthy Futures (FHF) Assessment + FHF | Intervention Type: BEHAVIORAL; Name: Fostering Healthy Futures (FHF); Assigned to Arm(s): Fostering Healthy Futures (FHF) Assessment + FHF
B: Arm Label: Family-Focused Psychosocial Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Family-Focused, Community-Based, Resilience-Targetting Psychosocial Intervention | Arm Label: Waiting List Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Family-Focused, Community-Based, Resilience-Targetting Psychosocial Intervention; Assigned to Arm(s): Family-Focused Psychosocial Intervention
C: Arm Label: Trauma-Focused Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Trauma-Focused Cognitive Behavioral Therapy | Arm Label: Waiting List Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trauma-Focused Cognitive Behavioral Therapy; Assigned to Arm(s): Trauma-Focused Cognitive Behavioral Therapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Risk Reduction through Family Therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Risk Reduction through Family Therapy | Intervention Type: BEHAVIORAL; Name: Risk Reduction through Family Therapy; Assigned to Arm(s): 1, 2

Answer: A